{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:57:58Z","timestamp":1793059078357,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clindermatol.2026.08.012","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:15:09Z","timestamp":1788448509000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Glucagon-like peptide-1 receptor agonist-associated injection site and dermatologic reactions"],"prefix":"10.1016","author":[{"given":"Dareen","family":"Elgindi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0749-4752","authenticated-orcid":false,"given":"Vesna","family":"Petronic-Rosic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2026.08.012_bib0001","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMra2500106","article-title":"GLP-1 receptor agonists","volume":"394","author":"Rosen","year":"2026","journal-title":"N Engl J Med."},{"key":"10.1016\/j.clindermatol.2026.08.012_bib0002","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1111\/jdv.20694","article-title":"The effects of GLP-1RA on inflammatory skin diseases: a comprehensive review","volume":"39","author":"Paschou","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2026.08.012_bib0003","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2024.5018","article-title":"Online advertising of compounded glucagon-like peptide-1 receptor agonists","volume":"6","author":"Chetty","year":"2025","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.clindermatol.2026.08.012_bib0004","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1900\/RDS.2014.11.202","article-title":"Adverse effects of GLP-1 receptor agonists","volume":"11","author":"Filippatos","year":"2014","journal-title":"Rev Diabet Stud"},{"key":"10.1016\/j.clindermatol.2026.08.012_bib0005","doi-asserted-by":"crossref","first-page":"413","DOI":"10.36849\/JDD.8605","article-title":"A retrospective comparative analysis of cutaneous adverse reactions in GLP-1 agonist therapies","volume":"24","author":"Daniel","year":"2025","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.clindermatol.2026.08.012_bib0006","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1111\/dom.70382","article-title":"Injection-site and dermatologic reactions associated with glucagon-like peptide-1 receptor agonists: insights from meta-analysis of randomised controlled trials and real-world evidence","volume":"28","author":"Taj","year":"2026","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clindermatol.2026.08.012_bib0007","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/j.1463-1326.2012.01561.x","article-title":"Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment","volume":"14","author":"Fineman","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clindermatol.2026.08.012_bib0008","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/dom.12640","article-title":"Low incidence of anti-drug antibodies in patients with type 2 diabetes treated with once-weekly glucagon-like peptide-1 receptor agonist dulaglutide","volume":"18","author":"Milicevic","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clindermatol.2026.08.012_bib0009","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.regpep.2006.02.007","article-title":"Glucagon-like peptide-1 receptor and proglucagon expression in mouse skin","volume":"134","author":"List","year":"2006","journal-title":"Regul Pept"},{"key":"10.1016\/j.clindermatol.2026.08.012_bib0010","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/exd.12081","article-title":"Increased expression of glucagon-like peptide-1 receptors in psoriasis plaques","volume":"22","author":"Faurschou","year":"2013","journal-title":"Exp Dermatol"},{"issue":"7542","key":"10.1016\/j.clindermatol.2026.08.012_bib0011","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature14022","article-title":"Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions","volume":"519","author":"McNeil","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.clindermatol.2026.08.012_bib0012","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/exd.14222","article-title":"MRGPRX2 sensing of cationic compounds-A bridge between nociception and skin diseases?","volume":"30","author":"Corbi\u00e8re","year":"2021","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.clindermatol.2026.08.012_bib0013","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3070","article-title":"Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?","volume":"35","author":"Gentilella","year":"2019","journal-title":"Diabetes Metab Res Rev"},{"issue":"2","key":"10.1016\/j.clindermatol.2026.08.012_bib0014","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4103\/jdds.jdds_5_19","article-title":"Liraglutide-Induced injection site reaction","volume":"23","author":"Neel","year":"2019","journal-title":"J Dermatol Dermatol Surg"},{"key":"10.1016\/j.clindermatol.2026.08.012_bib0015","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1463-1326.2011.01357.x","article-title":"An overview of once-weekly glucagon-like peptide-1 receptor agonists\u2013available efficacy and safety data and perspectives for the future","volume":"13","author":"Madsbad","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clindermatol.2026.08.012_bib0016","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2026.08.012_bib0017","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity","volume":"393","author":"Aronne","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2026.08.012_bib0018","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3390\/ph19030365","article-title":"Psychiatric adverse events and administration challenges associated with GLP-1 receptor agonists for weight loss: a real-world analysis","volume":"19","author":"Hindi","year":"2026","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.clindermatol.2026.08.012_bib0019","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1111\/dom.16376","article-title":"Adverse drug reaction patterns of GLP-1 receptor agonists approved for obesity treatment: disproportionality analysis from global pharmacovigilance database","volume":"27","author":"Kim","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clindermatol.2026.08.012_bib0020","unstructured":"Food and Drug Administration. Risk Assessment and Mitigation Review [Tirzepatide]. Application 215866Orig1s000. 2021. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2022\/215866Orig1s000RiskR.pdf. Accessed 6 Aug 2026."},{"key":"10.1016\/j.clindermatol.2026.08.012_bib0021","unstructured":"Food and Drug Administration. Bydureon Full Prescribing information. 2018. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/022200s026lbl.pdf. Accessed 6 Aug 2026."},{"key":"10.1016\/j.clindermatol.2026.08.012_bib0022","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S2213-8587(25)00226-8","article-title":"Once-weekly semaglutide 7\u00b72 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial","volume":"13","author":"Wharton","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.clindermatol.2026.08.012_bib0023","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S2213-8587(25)00225-6","article-title":"Once-weekly semaglutide 7\u00b72 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial","volume":"13","author":"Lingvay","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.clindermatol.2026.08.012_bib0024","doi-asserted-by":"crossref","first-page":"e426","DOI":"10.1093\/ajhp\/zxaf008","article-title":"Allodynia (skin tenderness) associated with semaglutide: a case series","volume":"82","author":"Stark","year":"2025","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.clindermatol.2026.08.012_bib0025","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s00228-026-04079-7","article-title":"Dysesthesia associated with GLP-1 agonist therapies: data-mining analysis and literature review","volume":"82","author":"Laroche","year":"2026","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.clindermatol.2026.08.012_bib0026","doi-asserted-by":"crossref","first-page":"G23","DOI":"10.1152\/ajpgi.00189.2019","article-title":"Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide stimulate release of substance P from TRPV1- and TRPA1-expressing sensory nerves","volume":"319","author":"Mayer","year":"2020","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.clindermatol.2026.08.012_bib0027","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.2337\/db25-0158","article-title":"Incretin receptors in the peripheral nervous system: implications for obesity treatment and peripheral neuropathy","volume":"74","author":"de Sousa","year":"2025","journal-title":"Diabetes"},{"key":"10.1016\/j.clindermatol.2026.08.012_bib0028","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(12)61267-7","article-title":"Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study","volume":"381","author":"Buse","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2026.08.012_bib0029","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2337\/ds20-0033","article-title":"Injection-site nodules associated with once-weekly subcutaneous administration of semaglutide","volume":"34","author":"Hearn","year":"2021","journal-title":"Diabetes Spectr"},{"key":"10.1016\/j.clindermatol.2026.08.012_bib0030","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2337\/diaspect.28.4.283","article-title":"Injection-site nodules associated with the use of exenatide extended-release reported to the U.S. Food and Drug Administration adverse event reporting system","volume":"28","author":"Jones","year":"2015","journal-title":"Diabetes Spectr"},{"key":"10.1016\/j.clindermatol.2026.08.012_bib0031","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0169-409X(97)00048-3","article-title":"Biodegradation and biocompatibility of PLA and PLGA microspheres","volume":"28","author":"Shive","year":"1997","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.clindermatol.2026.08.012_bib0032","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.smim.2007.11.004","article-title":"Foreign body reaction to biomaterials","volume":"20","author":"Anderson","year":"2008","journal-title":"Semin Immunol."},{"key":"10.1016\/j.clindermatol.2026.08.012_bib0033","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/cup.14193","article-title":"Exenatide-induced granulomatous panniculitis associated with poly(d,l-lactide-co-glycolide)","volume":"49","author":"Zhu","year":"2022","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.clindermatol.2026.08.012_bib0034","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1111\/cup.14110","article-title":"Carbol fuchsin stain enhances detection of poly-(d, l-lactide-co-glycolide) microspheres in exenatide extended-release cutaneous injection-site foreign body reaction","volume":"48","author":"Flugrad","year":"2021","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.clindermatol.2026.08.012_bib0035","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/DAD.0000000000000036","article-title":"Exenatide-induced eosinophilic sclerosing lipogranuloma at the injection site","volume":"36","author":"Shan","year":"2014","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.clindermatol.2026.08.012_bib0036","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1097\/DAD.0000000000000243","article-title":"Exenatide-induced eosinophil-rich granulomatous panniculitis: a novel case showing injected microspheres","volume":"37","author":"Andr\u00e9s-Ramos","year":"2015","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.clindermatol.2026.08.012_bib0037","article-title":"Slow versus fast subcutaneous heparin injections for prevention of bruising and site pain intensity","volume":"6","author":"Mohammady","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clindermatol.2026.08.012_bib0038","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1749-6632.2010.05820.x","article-title":"Neuroendocrine responses to hypoglycemia","volume":"1212","author":"Tesfaye","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.clindermatol.2026.08.012_bib0039","first-page":"463","article-title":"Glucose counterregulatory responses to hypoglycemia","volume":"9","author":"Sprague","year":"2011","journal-title":"Pediatr Endocrinol Rev"},{"key":"10.1016\/j.clindermatol.2026.08.012_bib0040","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1001\/jamacardio.2020.1966","article-title":"Use of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and cardiovascular disease: a review","volume":"5","author":"Honigberg","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.clindermatol.2026.08.012_bib0041","doi-asserted-by":"crossref","first-page":"9613","DOI":"10.1038\/s41598-017-10110-w","article-title":"Effective method for drug injection into subcutaneous tissue","volume":"7","author":"Kim","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.clindermatol.2026.08.012_bib0042","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/jocn.12291","article-title":"The effect of injection duration and injection site on pain and bruising of subcutaneous injection of heparin","volume":"23","author":"Pourghaznein","year":"2014","journal-title":"J Clin Nurs"},{"key":"10.1016\/j.clindermatol.2026.08.012_bib0043","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s11095-025-03841-3","article-title":"Clinical evaluation of the temperature dependence of subcutaneous injection experience in healthy volunteers","volume":"42","author":"Shi","year":"2025","journal-title":"Pharm Res"}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X26002221?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X26002221?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:50:41Z","timestamp":1791316241000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X26002221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":43,"alternative-id":["S0738081X26002221"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2026.08.012","relation":{},"ISSN":["0738-081X"],"issn-type":[{"value":"0738-081X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucagon-like peptide-1 receptor agonist-associated injection site and dermatologic reactions","name":"articletitle","label":"Article Title"},{"value":"Clinics in Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clindermatol.2026.08.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}